Roni Shouval, MD, PhD

Assistant Attending, Adult Bone Marrow Transplantation Service, Cellular Therapy Service
The Precision Cellular Therapy Laboratory
Publications
Jobs
Members

Roni Shouval, MD, PhD

Assistant Attending, Adult Bone Marrow Transplantation Service, Cellular Therapy Service
Share
Share
Roni Shouval

Email

shouvalr@mskcc.org

Education

MD: Technion, Israel Institute of Technology | Haifa, Israel; PhD: Bar Ilan University | Ramat Gan, Israel

Research Interest

Roni Shouval, MD, PhD, is Director of the Precision Cellular Therapy Laboratory and an attending on the Adult Bone Marrow Transplantation and Cellular Therapy Service at Memorial Sloan Kettering Cancer Center. His research focuses on deciphering mechanisms of resistance and toxicity in chimeric antigen receptor (CAR) T-cell therapy and hematopoietic cell transplantation (HCT). He integrates multiomic data—including genomic, transcriptomic, proteomic, radiomic, and microbiome profiles—with advanced computational approaches to uncover drivers of treatment failure and adverse events. Work from the Precision Cellular Therapy Laboratory informs clinical trial design and guides precision interventions aimed at improving the safety and efficacy of cellular therapies in hematologic malignancies.

Awards and Honors

  • Comedy vs. Cancer Research Grant (2024)
  • National Cancer Institute/National Institutes of Health – K08 Career Development Award (2023–2028)
  • Lymphoma Research Foundation (LRF) Clinical Investigator Career Development Award (2023-205)
  • Scholar Award, American Society of Hematology (2021–2023)
  • New Investigator Award, American Society for Transplantation and Cellular Therapy (2020–2022)
  • The 2013 Pinchas Borenstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Israel (2013-2018)

Publications

Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, Bücklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N Dr, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini MC, Raj SS, Rajeeve S, Salles GA, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid OB, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R. T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy. Blood. 2025 Apr 21;. doi: 10.1182/blood.2025028833. [Epub ahead of print] PubMed PMID: 40258181.

Raj SS, Fei T, Fried S, Ip A, Fein JA, Leslie LA, Alarcon Tomas A, Leithner D, Peled JU, Corona M, Dahi PB, Danylesko I, Epstein-Peterson Z, Funnell T, Giralt SA, Jacoby E, Kedmi M, Landego I, Lin RJ, Parascondola A, Pascual L, Orozco N, Park JH, Palomba ML, Salles G, Saldia A, Schöder H, Sdayoor I, Shah GL, Scordo M, Shem-Tov N, Shimoni A, Slingerland J, Yerushalmi R, Nagler A, Greenbaum BD, Vickers AJ, Suh HC, Avigdor A, Perales MA, van den Brink MRM, Shouval R. An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nat Med. 2025 Apr;31(4):1183-1194. doi: 10.1038/s41591-025-03532-x. Epub 2025 Apr 1. PubMed PMID: 40169864; PubMed Central PMCID: PMC12003198.

Shouval R, Waters NR, Gomes ALC, Zuanelli Brambilla C, Fei T, Devlin SM, Nguyen CL, Markey KA, Dai A, Slingerland JB, Clurman AG, Fontana E, Amoretti LA, Wright RJ, Hohl TM, Taur Y, Sung AD, Weber D, Hashimoto D, Teshima T, Chao NJ, Holler E, Scordo M, Giralt SA, Perales MA, Peled JU, van den Brink MRM. Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation. Clin Cancer Res. 2023 Jan 4;29(1):165-173. doi: 10.1158/1078-0432.CCR-22-1254. PubMed PMID: 36322005; PubMed Central PMCID: PMC9812902.

Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard JE, Giebel S, Gilleece MH, Giralt S, Jakubowski A, Montoto S, O’Reilly RJ, Papadopoulos EB, Peric Z, Ruggeri A, Sanz J, Sauter CS, Savani BN, Schmid C, Spyridonidis A, Tamari R, Versluis J, Yakoub-Agha I, Perales MA, Mohty M, Nagler A. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021 Mar;8(3):e205-e215. doi: 10.1016/S2352-3026(20)30394-X. PubMed PMID: 33636142; PubMed Central PMCID: PMC9190021.

Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, Steingart RM, Mahmood SS, Schaffer WL, Perales MA, Shouval R. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J Am Coll Cardiol. 2021 Nov 2;78(18):1800-1813. doi: 10.1016/j.jacc.2021.08.044. PMID: 34711339; PMCID: PMC8562317.

Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, Olaide Afuye A, Alperovich A, Anagnostou T, Besser MJ, Batlevi CL, Dahi PB, Devlin SM, Fingrut WB, Giralt SA, Lin RJ, Markel G, Salles G, Sauter CS, Scordo M, Shah GL, Shah N, Scherz-Shouval R, van den Brink M, Perales MA, Palomba ML. Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2022 Feb 1;40(4):369-381. doi: 10.1200/JCO.21.02143. Epub 2021 Dec 3. PubMed PMID: 34860572; PubMed Central PMCID: PMC8797602.

View a full listing of Roni Shouval’s journal articles.

Social Media

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Roni Shouval discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures